Molecular Profile Detail

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial	Phase	Therapies	Title	Recruitment Status	Covered Countries	Other Countries
NCT03317119	Phase I	Trametinib + Trifluridine-tipiracil hydrochloride	Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery	Completed	USA	0
NCT05379972	Phase II	Olaparib + Pembrolizumab	Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers	Active, not recruiting	USA	0
NCT01884285	Phase I	AZD8186 Abiraterone + AZD8186 AZD8186 + Vistusertib	AZD8186 First Time In Patient Ascending Dose Study	Completed	USA \| GBR \| ESP \| CAN	0
NCT02189174	Phase Ib/II	CLR457	Study of CLR457 Administered Orally in Adult Patients With Advanced Solid Malignancies	Terminated	USA \| ESP \| CAN	2
NCT03842228	Phase I	Copanlisib + Durvalumab + Olaparib	Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations	Active, not recruiting	USA	0
NCT02920450	Phase Ib/II	Carboplatin + Gedatolisib + Paclitaxel	Study of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC (UF-STO-LUNG-002)	Terminated	USA	0
NCT04486352	Phase Ib/II	Atezolizumab + Talazoparib Atezolizumab + Ipatasertib Abemaciclib + Giredestrant Inavolisib + Letrozole	A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer (EndoMAP)	Recruiting	USA	0
NCT04108858	Phase Ib/II	Copanlisib + Pertuzumab + Trastuzumab Pertuzumab + Trastuzumab	Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer	Terminated	USA	0
NCT06941480	Phase I	177Lu-DTPA-SC16	A Study of 177Lu-DTPA-SC16.56 in People With Neuroendocrine Carcinomas of the Lung and Prostate	Not yet recruiting	USA	0
NCT05455619	Phase Ib/II	Capivasertib + Fulvestrant + SDX-7320 Alpelisib + Fulvestrant + SDX-7320	Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/ Her2- Breast Cancer (Amelia-1)	Recruiting	USA	0
NCT06764186	Phase III	Capivasertib + Fulvestrant	A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain (CAPItana)	Recruiting	ESP	0
NCT05843253	Phase II	Ribociclib + Temozolomide Everolimus + Ribociclib	Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant	Recruiting	USA \| NLD \| GBR \| DEU \| CAN \| AUS	0
NCT03218826	Phase I	AZD8186 + Docetaxel	PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery	Active, not recruiting	USA	0
NCT05111561	Phase I	Binimetinib + ZEN-3694	Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer	Suspended	USA	0
NCT04216472	Phase II	Alpelisib + Nab-paclitaxel	Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations	Terminated	USA	0
NCT05082025	Phase II	Copanlisib + Fulvestrant	Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations	Active, not recruiting	USA	0
NCT02401347	Phase II	Talazoparib	Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors	Completed	USA	0
NCT04770246	Phase II	TAS-117	TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Mutations	Terminated	USA \| GBR \| FRA \| AUT	0
NCT02761694	Phase I	ARQ 751 + Paclitaxel ARQ 751 ARQ 751 + Fulvestrant	ARQ 751 as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations	Terminated	USA	0
NCT04317105	Phase Ib/II	Copanlisib + Ipilimumab + Nivolumab Copanlisib + Nivolumab	Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN	Active, not recruiting	USA \| CAN	0
NCT06239467	Phase I	OKI-219 + Trastuzumab + Tucatinib OKI-219 Fulvestrant + OKI-219 + PF-07220060 Fulvestrant + OKI-219 Fulvestrant + OKI-219 + Ribociclib	First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer (PIKture-01)	Recruiting	USA \| ITA \| FRA \| ESP \| BEL	1
NCT06085729	Phase Ib/II	ADI-PEG 20 + Cabazitaxel + Carboplatin	Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)	Recruiting	USA	0
NCT04632992	Phase II	Ipatasertib Atezolizumab + Capecitabine Entrectinib Atezolizumab + Docetaxel Ado-trastuzumab emtansine + Atezolizumab Capecitabine + Pertuzumab/trastuzumab/hyaluronidase-zzxf Paclitaxel + Pertuzumab/trastuzumab/hyaluronidase-zzxf Alectinib Inavolisib Pertuzumab/trastuzumab/hyaluronidase-zzxf Docetaxel + Pertuzumab/trastuzumab/hyaluronidase-zzxf Atezolizumab + Paclitaxel Ado-trastuzumab emtansine + Tucatinib	A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response (MyTACTIC)	Completed	USA	0
NCT03209401	Phase I	Carboplatin + Niraparib	Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies	Terminated	USA	0
NCT05038839	Phase I	Cabozantinib + Pamiparib	Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors	Active, not recruiting	USA	0
NCT05554380	Phase II	Ipatasertib + Paclitaxel	Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With AKT Mutations, A ComboMATCH Treatment Trial	Recruiting	USA	1
NCT06982521	Phase III	Fulvestrant + RLY-2608 Capivasertib + Fulvestrant	Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer (ReDiscover-2)	Recruiting	USA	0
NCT05010096	Phase I	Copanlisib + Elimusertib	BAY1895344 and Copanlisib for the Treatment of Molecularly Selected Patients With Advanced Solid Tumors	Withdrawn		0
NCT05039801	Phase I	Capivasertib + IACS-6274 Bevacizumab + IACS-6274 + Paclitaxel IACS-6274	IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors	Recruiting	USA	0
NCT01097278	Phase 0	Cholecalciferol	S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer	Completed	USA	0

Profile Name	PTEN inact mut
Gene Variant Detail	PTEN inact mut (loss of function)
Relevant Treatment Approaches	Akt Inhibitor (Pan) Akt1 Inhibitor Akt2 Inhibitor PI3K Inhibitor (Pan) PIK3CB inhibitor

Molecular Profile Detail

Contact

Filtering

Sorting